Time to Next Systemic Therapy After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer
In this cohort, patients with oligoprogressive mCRPC treated with SBRT delayed the next line of systemic therapy for a median of 10.1 months. SBRT in patients with oligoprogressive mCRPC may delay initiation of the next-line systemic therapy in well-selected patients, including those with ≥1 untreated nonprogressing metastasis.
Authors
- Nellowe Candelario (ORCID: https://orcid.org/0000-0003-3153-7428)
- Tyler P. Robin (ORCID: https://orcid.org/0000-0002-0211-5552)
- Corbin Eule (ORCID: https://orcid.org/0000-0002-8430-1040)
- Sameer K. Nath
Institutions
- Fred Hutch Cancer Center (US)
- University of Colorado Cancer Center (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2024-10-20
- DOI
- https://doi.org/10.1016/j.adro.2024.101655
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09